CSC biomarkers are promising therapeutic targets, oncolytic measles viruses targeting CD133+ cells and EpCAM/CD3 and CD44 antibodies were invented in HCC (100–102). This evidence concerns the gene PROM1 and hepatocellular carcinoma.